ORIC’s senior management team has decades of experience in the biotech and pharmaceutical industries, having worked in drug discovery and development at companies such as Genentech, Merck, Pfizer, Biogen, Medivation and Ignyta.
Jacob Chacko, MD
Chief Executive Officer
Dr. Chacko was most recently CFO of Ignyta, a NASDAQ-listed precision oncology company acquired by Roche in February 2018. At Ignyta, he had a broad operational role and helped raise over $500 million in capital. During his tenure, the company grew from fewer than 20 employees and a $50 million enterprise value to 125 employees and a $1.7 billion enterprise value at the time of acquisition. Prior to Ignyta, Dr. Chacko was an investor at TPG Capital, where he helped lead teams that completed acquisitions having an aggregate value of over $10 billion. He has served on the board of directors of Bonti, RentPath and EnvisionRx and was a board observer to Par Pharmaceutical, IMS Health and Quintiles Transnational. He previously served on the board of the Packard Children’s Health Alliance at the Lucile Packard Children’s Hospital Stanford.
Dr. Chacko concurrently received his MD with AOA honors from UCLA and his MBA with Distinction from Harvard Business School. Prior to that, he was a consultant serving healthcare clients at McKinsey & Company. He received a MSc from Oxford University as a Marshall Scholar and undergraduate degrees from the University of Southern California, where he graduated as the University Valedictorian. He currently serves on the board of directors of Turning Point Therapeutics (NASDAQ: TPTX) and 4D Molecular Therapeutics, and chairs the Western Regional Selection Committee for the Marshall Scholarship.
Lori Friedman, PhD
Chief Scientific Officer
Dr. Friedman brings to ORIC over 20 years of experience in cancer research, including expertise in cancer target discovery and validation, signal transduction, cancer genetics, drug discovery, pharmacology and biomarkers. During her 15-year career at Genentech, she held roles of increasing responsibility and was most recently head of translational oncology for Genentech Research and Early Development (gRED), where her team advanced more than 20 programs into clinical development. Dr. Friedman also sat on multiple cross-functional leadership teams tasked with strategic and technical review of Genentech’s oncology research pipeline projects.
Prior to Genentech, Dr. Friedman held various scientific leadership roles at Exelixis. She is an inventor on 24 issued patents and author on 88 peer-reviewed publications. She completed post-doctoral work at the University of Washington and at Cambridge University and earned a PhD in molecular and cell biology from UC Berkeley.
Pratik Multani, MD
Chief Medical Officer
Dr. Multani brings to ORIC more than 20 years of experience in oncology drug development and treatment of patients with cancer. Most recently, Dr. Multani served as Chief Medical Officer of Ignyta, which was acquired by Roche, where he led all development and regulatory activities related to multiple clinical stage assets, including Ignyta’s lead program entrectinib, which is in a global, registrational study across 15 countries.
Prior to Ignyta, Dr. Multani was Chief Medical Officer of Fate Therapeutics, and prior to that held multiple leadership positions at Kalypsys, Kanisa, and Salmedix. Dr. Multani started his biotech career at Biogen Idec, where he was involved with the development of both Zevalin and Rituxan for treatment of Non-Hodgkin Lymphoma.
Prior to his career in biotech, Dr. Multani held academic and clinical positions at Harvard Medical School and at Massachusetts General Hospital. His postdoctoral training included a fellowship in hematology and oncology at Dana-Farber/Partners and an internship and residency in Internal Medicine at Massachusetts General Hospital. Dr. Multani received an MD from Harvard Medical School and an MS in clinical epidemiology from Harvard School of Public Health.
Chief Business Officer
Prior to joining ORIC, Mr. Panuwat was Senior Vice President of Business Development at Prothena, where he led partnership activities and established the company’s global research & development collaboration with Celgene. Prior to Prothena, he was Head of Business Development at Medivation, where he led M&A and licensing activities, including the acquisition of talazoparib from BioMarin, until Medivation’s acquisition by Pfizer. He was also previously in corporate development at Questcor until its merger with Mallinckrodt, and spent nearly a decade in the Global Healthcare Investment Banking Group at Merrill Lynch. He holds a BS in Biology from Santa Clara University, an MS in Physiology and Biophysics from Georgetown University, and an MBA from UCLA.
Edna Chow Maneval, PhD
Senior Vice President, Clinical Development
Dr. Chow Maneval brings to ORIC 20 years of clinical development experience in oncology. Most recently, she was Senior Vice President of Clinical Development at Ignyta (acquired by Roche in 2018), where she was the clinical lead for entrectinib, a molecularly-targeted therapy for rare cancers affecting adults and pediatric patients. Prior to Ignyta, she was Vice President of Clinical Development at Aragon (acquired by Johnson & Johnson in 2013) and Seragon (acquired by Genentech in 2014), responsible for the apalutamide (ERLEADA™) and SERD clinical programs in prostate and breast cancers, respectively. Dr. Chow Maneval’s career in drug development started at Pfizer where she held positions of increasing responsibility within the oncology group, mostly dedicated to the development and approval of sunitinib (SUTENT®). In 2013, Dr. Chow Maneval was a YWCA TWIN (Tribute to Women & Industry) Honoree. She holds a PhD in Biomedical Engineering from the University of Southern California.
Vice President, Human Resources
Brian Muma has a broad background in human resources with deep understanding of the biopharmaceutical industry acquired from HR leadership positions across the spectrum from discovery to commercialization. Mr. Muma was previously Vice President of Human Resources for Roche China. Prior to the assignment in China, Brian held senior HR leadership roles at Genentech in R&D, Manufacturing, Commercial Operations and Total Rewards Strategy. Earlier in his career, he was an executive compensation consultant at KPMG and Mercer.
Mr. Muma has completed certification courses in change management, advanced project management and 360 degree feedback as well as advanced training in executive coaching and emotional intelligence. He holds a Bachelors degree in Economics and an MBA from the University of Michigan.
Krys Corbett, JD
General Counsel & Corporate Secretary
Krys Corbett has more than 20 years of experience in licensing transactions, business development and alliance management, including more than 15 in biopharma.
In previous roles at Genentech and Roche, Ms. Corbett focused on strategic alliances and transactions in Roche Partnering, Genentech Alliance Management and Portfolio Planning, and Genentech Transactional Law. She led transactions for licensing, launch or label expansions of Venclexta®, Lucentis®, Rituxan Hycela®, Erivedge®, and development-stage assets, and provided legal and partnering support for products including Avastin®, Xolair®, Rituxan®, and Cotellic®.
Prior to Genentech/Roche, she was at Wilson Sonsini Goodrich and Rosati, where she advised clients on licensing and M&A transactions. She received her JD with honors from Duke University School of Law.
Senior Director of Finance & Operations
Sara Coblin previously worked as Director of Finance at Genentech supporting global CMC operations. Prior to that role, she held other finance positions in R&D, FP&A and Alliance Management supporting partnerships on Ocrevus®, Rituxan®, Tarceva® and many other pipeline programs. Earlier in her career, she worked at Sun Microsystems and Arthur Andersen specializing in business process improvement and ERP systems implementation.
She holds a BA in Economics and Computer Applications from the University of Notre Dame. She also earned an MBA from University of California, Berkeley.